Precision EV enrichment and biomarker discovery for liquid biopsies
Transition from biological noise to actionable multiomic disease signatures with exoBAMS™ technology.
Multiomic and multiparametric immunoassays for early diagnostics and disease staging in oncology, neurology, inflammation, autoimmune, metabolic and other diseases
Start a ProjectTechnology
Traditional EV isolation methods capture everything. We capture what matters.
BAMS™ and exoBAMS™ are protected by US Patents 12,467,930, 12,019,070, 11,913,964, 11,639,938, 11,391,729, 11,131,674, 10,451,631, 10,101,336 and 9,618,520.
Other US and international patents pending
STANDARD BULK ISOLATION
Current EV enrichment methods isolate multiple populations and clutter targets with non-specific protein contamination
exoBAMS™ TARGETED CAPTURE
Immunoaffinity-based capture methods isolate precise EV populations for developing actionable disease signatures
exoBAMS™ Technology: An Integrated Workflow
exoBAMS™ Reagents: Precision Immunocapture
exoBAMS™ reagents are designed for the immunocapture (selective enrichment) of disease-specific exosomes and other EV types from biofluids and conditioned media. This targeted approach dramatically improves the signal-to-noise ratio, ensuring that subsequent analyses focus on the most relevant molecular information.
Data Acquisition: Maximizing Information Content
Proprietary methods of processing and measuring the captured exosome/EV populations have the key objective to maximize the information content derived from these small, complex vesicles. This involves sophisticated handling techniques that preserve the integrity of the captured material to detect a wide array of molecular components (proteins, metabolites, lipids) with extreme sensitivity and resolution.
Data Analytics: Molecular Signatures
Finally, the measurement data generated from multiple exoBAMS™ experiments are fed into powerful data analytics engines. This analysis can identify patterns and relationships within massive datasets. The goal is to create "molecular signatures" of diseases. These are unique combinations of different molecular features that specifically and reliably characterize a disease state, its progression, or even response to treatment. By comparing unknown samples against these established signatures, exoBAMS™ technology can provide valuable diagnostic or prognostic insights.
Umatched Sensitivity
Targeted immunoaffinity enrichment allows for the capture of exceptionally rare EV populations—such as early-stage tumor-derived or brain-specific vesicles—from minimal sample volumes. We pull the needle from the haystack, enabling early detection and precise disease monitoring.
Streamlined Speed
Time is critical in translational research and diagnostic development. The exoBAMS™ workflow replaces multi-day, labor-intensive isolation protocols with a streamlined, bead-based capture process. This rapid turnaround accelerates custom assay development from months to weeks.
Maximized Information
High purity equals high clarity. By eliminating co-isolated lipoproteins and protein aggregates, our platform delivers incredibly clean exosome fractions. This maximizes the signal-to-noise ratio for downstream multiomic profiling, allowing you to confidently extract transcriptomic, lipidomic and proteomic data from a single enriched sample.
Case Examples
Explore how the exoBAMS™ platform isolates distinct multiomic patterns from complex background noise in human plasma samples.
These highlighted examples demonstrate the baseline precision of the exoBAMS™ workflow for clinical research achieving clear separation using only fundamental Principal Component Analysis (PCA). To unlock advanced supervised learning models, access our full, unpublished validation data, and apply this proprietary resolution to your own biomarker discovery—contact us to explore a custom assay partnership.
Services
Your discovery. Powered by exoBAMS™
At the core of our business is a commitment to advancing liquid biopsy and biomarker discovery. We do not simply sell off-the-shelf consumables. Instead, we offer our proprietary immunoaffinity reagents exclusively through specialized custom assay development partnerships.
By partnering with our analytical services team, you gain direct access to the exoBAMS™ platform and our deep expertise in exosome and EV isolation. We work side-by-side with your research team to design, optimize, and execute assays tailored to your specific clinical or diagnostic goals.
Our Collaborative Process
Consultation & Target Strategy
We consult with your team to understand your clinical or research objectives. Whether you are profiling prostate cancer stages, investigating microglial activation in Alzheimer's, or characterizing total exosome output, we select or customize our workflow for your target and species.
High-Fidelity Enrichment
Using the exoBAMS™ platform, our analytical team processes your complex sample matrices (plasma, serum or conditioned media). Our reagents bind specifically to the target EV surface markers, washing away the complex biological background.
Multiomic Profiling and Validation
The highly purified EV fractions are seamlessly transitioned into downstream analysis. We work with you to generate the data you need, whether that involves protein, lipid or metabolomic profiling, or next-generation sequencing (NGS) of exosomal RNA.
Deliverables & Scale-Up
You receive comprehensive, validated data sets and a custom-developed assay protocol optimized for your specific downstream applications, ready for your next phase of research or clinical development.
Why Partner With Us?
- Exclusive Technology Access – Utilize highly specific reagents unavailable anywhere else on the market.
- Liquid Biopsy Expertise – Leverage our team's deep understanding of biomarker discovery and multiomic analysis.
- Accelerated Timelines – Bypass the months of trial-and-error typically associated with optimizing standard EV isolation methods.
- Disease-Specific Focus – Build assays utilizing reagents already validated for complex fields like early-stage cancer detection, brain cell typing, and mixed pathologies.
About Us
PUSHING THE BOUNDARIES OF BIOANALYSIS
To accelerate the development of high-resolution liquid biopsies and advanced diagnostics by providing researchers with unparalleled access to pure, disease-specific exosome and EV populations.
The potential of extracellular vesicles as sources of critical biomarkers for early disease detection and treatment monitoring is clear. However, the true promise of these particles has long been bottlenecked by outdated isolation technologies. Methods that rely on size or density separation inevitably co-isolate massive amounts of non-specific proteins and cellular debris, obscuring the very signals researchers are trying to find. We recognized that the next leap in diagnostics and drug development required a fundamental shift in bioanalytical methodology. It required precision.
Our team of scientists and bioengineers developed the exoBAMS™ (exosome Bead Assisted Mass Spectrometry) platform to solve the purity problem. By utilizing highly specific, cataloged immunoaffinity reagents, we enable the targeted enrichment of distinct exosome subpopulations—whether derived from specific brain cells, distinct tumor types, or broad biofluid populations.
We operate at the intersection of sensitivity, speed, and information content. We are not just a reagent supplier; we are an analytical partner. By integrating our proprietary reagents with our custom assay development services, we empower our partners to extract robust lipidomic, proteomic and transcriptomic data from the most complex sample matrices. From early-stage cancer detection to neurological disease subtyping, we are here to help you isolate the signals that drive clinical innovation.
Partner with us on Custom Pilot Projects
We are currently opening a select number of slots for custom analytical assay pilot projects. By partnering with us, your team gains access to dedicated development resources to build, optimize, and validate an exoBAMS™ assay tailored specifically to your unique R&D goals.
Whether you are looking to profile specific exosome surface markers or streamline your bioanalytical workflows, we can build the exact tool you need to accelerate your pipeline.